These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 10853816

  • 1. Fluorodeoxyglucose PET in the initial staging of germ cell tumours.
    Hain SF, O'Doherty MJ, Timothy AR, Leslie MD, Partridge SE, Huddart RA.
    Eur J Nucl Med; 2000 May; 27(5):590-4. PubMed ID: 10853816
    [Abstract] [Full Text] [Related]

  • 2. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours.
    Spermon JR, De Geus-Oei LF, Kiemeney LA, Witjes JA, Oyen WJ.
    BJU Int; 2002 Apr; 89(6):549-56. PubMed ID: 11942962
    [Abstract] [Full Text] [Related]

  • 3. [Fluorodeoxyglucose (FDO) positron emission tomography (PET) in testicular germ cell tumors in adults: preliminary French clinical evaluation, development of the technique and its clinical applications].
    Maszelin P, Lumbroso J, Theodore C, Foehrenbach H, Merlet P, Syrota A.
    Prog Urol; 2000 Dec; 10(6):1190-9. PubMed ID: 11217558
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours.
    Lassen U, Daugaard G, Eigtved A, Højgaard L, Damgaard K, Rørth M.
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):396-402. PubMed ID: 12634968
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. FDG PET for detection and therapy control of metastatic germ cell tumor.
    Cremerius U, Effert PJ, Adam G, Sabri O, Zimmy M, Wagenknecht G, Jakse G, Buell U.
    J Nucl Med; 1998 May; 39(5):815-22. PubMed ID: 9591582
    [Abstract] [Full Text] [Related]

  • 8. False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma.
    Decoene J, Winter C, Albers P.
    Urol Oncol; 2015 Jan; 33(1):23.e15-23.e21. PubMed ID: 25454484
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Significance of 18F-FDG PET/CT in Characterization of Equivocal Lesions in High-Risk Testicular Carcinoma in Restaging Setting.
    Rasheed R, Al-Kandari F, Ghanem M, Marafi F, Usmani S.
    Asian Pac J Cancer Prev; 2020 Feb 01; 21(2):511-515. PubMed ID: 32102532
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma.
    De Santis M, Bokemeyer C, Becherer A, Stoiber F, Oechsle K, Kletter K, Dohmen BM, Dittrich C, Pont J.
    J Clin Oncol; 2001 Sep 01; 19(17):3740-4. PubMed ID: 11533096
    [Abstract] [Full Text] [Related]

  • 18. Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET.
    Bokemeyer C, Kollmannsberger C, Oechsle K, Dohmen BM, Pfannenberg A, Claussen CD, Bares R, Kanz L.
    Br J Cancer; 2002 Feb 12; 86(4):506-11. PubMed ID: 11870528
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.